ES2658413T3 - Fase cristalina de (3S,3S') 4,4'-disulfanodiilbis(ácido 3-aminobutano 1-sulfónico) con L-lisina - Google Patents

Fase cristalina de (3S,3S') 4,4'-disulfanodiilbis(ácido 3-aminobutano 1-sulfónico) con L-lisina Download PDF

Info

Publication number
ES2658413T3
ES2658413T3 ES13779603.3T ES13779603T ES2658413T3 ES 2658413 T3 ES2658413 T3 ES 2658413T3 ES 13779603 T ES13779603 T ES 13779603T ES 2658413 T3 ES2658413 T3 ES 2658413T3
Authority
ES
Spain
Prior art keywords
lysine
disulfanodiylbis
aminobutane
sulfonic acid
crystalline phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13779603.3T
Other languages
English (en)
Spanish (es)
Inventor
Fabrice Balavoine
Jean-Marie Schneider
Gérard Coquerel
Nicolas Couvrat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quantum Genomics SA
Original Assignee
Quantum Genomics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quantum Genomics SA filed Critical Quantum Genomics SA
Application granted granted Critical
Publication of ES2658413T3 publication Critical patent/ES2658413T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/26—Separation; Purification; Stabilisation; Use of additives
    • C07C319/28—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/66—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES13779603.3T 2012-10-22 2013-10-22 Fase cristalina de (3S,3S') 4,4'-disulfanodiilbis(ácido 3-aminobutano 1-sulfónico) con L-lisina Active ES2658413T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306307 2012-10-22
EP12306307.5A EP2722327A1 (en) 2012-10-22 2012-10-22 Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine
PCT/EP2013/072028 WO2014064077A1 (en) 2012-10-22 2013-10-22 Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine

Publications (1)

Publication Number Publication Date
ES2658413T3 true ES2658413T3 (es) 2018-03-09

Family

ID=47278723

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13779603.3T Active ES2658413T3 (es) 2012-10-22 2013-10-22 Fase cristalina de (3S,3S') 4,4'-disulfanodiilbis(ácido 3-aminobutano 1-sulfónico) con L-lisina

Country Status (30)

Country Link
US (2) US9278921B2 (cg-RX-API-DMAC7.html)
EP (2) EP2722327A1 (cg-RX-API-DMAC7.html)
JP (1) JP6317358B2 (cg-RX-API-DMAC7.html)
KR (1) KR102103407B1 (cg-RX-API-DMAC7.html)
CN (1) CN104768927B (cg-RX-API-DMAC7.html)
AR (1) AR093070A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013336738B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015008931B1 (cg-RX-API-DMAC7.html)
CA (1) CA2884914C (cg-RX-API-DMAC7.html)
CY (1) CY1119913T1 (cg-RX-API-DMAC7.html)
DK (1) DK2909169T3 (cg-RX-API-DMAC7.html)
EA (1) EA024460B1 (cg-RX-API-DMAC7.html)
ES (1) ES2658413T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180189T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036037T2 (cg-RX-API-DMAC7.html)
IL (1) IL237733B (cg-RX-API-DMAC7.html)
IN (1) IN2015DN02807A (cg-RX-API-DMAC7.html)
LT (1) LT2909169T (cg-RX-API-DMAC7.html)
ME (1) ME02955B (cg-RX-API-DMAC7.html)
MX (1) MX353693B (cg-RX-API-DMAC7.html)
NO (1) NO2909169T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ706070A (cg-RX-API-DMAC7.html)
PL (1) PL2909169T3 (cg-RX-API-DMAC7.html)
PT (1) PT2909169T (cg-RX-API-DMAC7.html)
RS (1) RS56896B1 (cg-RX-API-DMAC7.html)
SI (1) SI2909169T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800086T1 (cg-RX-API-DMAC7.html)
TW (1) TWI643842B (cg-RX-API-DMAC7.html)
WO (1) WO2014064077A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503574B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103951562B (zh) * 2014-05-09 2016-04-20 四川九章生物化工科技发展有限公司 一种绿原酸晶型及其制备方法
WO2022225712A1 (en) * 2021-04-22 2022-10-27 Teva Pharmaceuticals International Gmbh Solid state forms of firibastat and processes for preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235687B2 (en) * 2002-07-16 2007-06-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Derivatives of 4,4′-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same
FR2858617A1 (fr) * 2003-08-06 2005-02-11 Inst Nat Sante Rech Med Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
EP2439192A1 (en) 2010-10-07 2012-04-11 Quantum Genomics Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid)
US9447050B2 (en) * 2011-04-05 2016-09-20 The Translational Genomics Research Institute Solid forms of curcumin

Also Published As

Publication number Publication date
PL2909169T3 (pl) 2018-07-31
KR20150072454A (ko) 2015-06-29
RS56896B1 (sr) 2018-04-30
US9278921B2 (en) 2016-03-08
NO2909169T3 (cg-RX-API-DMAC7.html) 2018-06-02
BR112015008931A2 (pt) 2017-07-04
CA2884914C (en) 2021-01-05
JP6317358B2 (ja) 2018-04-25
TW201418202A (zh) 2014-05-16
HRP20180189T1 (hr) 2018-04-20
AR093070A1 (es) 2015-05-13
HK1212321A1 (en) 2016-06-10
DK2909169T3 (en) 2018-02-26
PT2909169T (pt) 2018-02-26
US20160221940A1 (en) 2016-08-04
SI2909169T1 (en) 2018-04-30
IN2015DN02807A (cg-RX-API-DMAC7.html) 2015-09-11
MX353693B (es) 2018-01-24
CN104768927B (zh) 2017-06-09
US20150284325A1 (en) 2015-10-08
MX2015005059A (es) 2015-11-23
EP2722327A1 (en) 2014-04-23
AU2013336738B2 (en) 2017-05-18
HUE036037T2 (hu) 2018-06-28
ME02955B (me) 2018-07-20
CA2884914A1 (en) 2014-05-01
EA201500438A1 (ru) 2015-09-30
KR102103407B1 (ko) 2020-04-22
NZ706070A (en) 2018-11-30
SMT201800086T1 (it) 2018-05-02
WO2014064077A1 (en) 2014-05-01
IL237733B (en) 2019-03-31
EP2909169A1 (en) 2015-08-26
LT2909169T (lt) 2018-04-25
CN104768927A (zh) 2015-07-08
BR112015008931B1 (pt) 2021-05-18
CY1119913T1 (el) 2018-06-27
TWI643842B (zh) 2018-12-11
AU2013336738A1 (en) 2015-04-09
EA024460B1 (ru) 2016-09-30
ZA201503574B (en) 2016-01-27
EP2909169B1 (en) 2018-01-03
JP2015536316A (ja) 2015-12-21
US9487477B2 (en) 2016-11-08

Similar Documents

Publication Publication Date Title
RU2012110715A (ru) Способ получения микрокапсул
EP2881446A3 (en) Organic compound and organic light emitting diode using the same
EA201590296A1 (ru) Дейтерированный ибрутиниб
IN2012DE00621A (cg-RX-API-DMAC7.html)
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
DOP2013000249A (es) Monohidrato de derivados de aza-adamantano
BR112016022437A2 (pt) Processo para preparação de (2s,5r)-6-(benziloxi)-7-oxo-1,6- diazabiciclo[3,2,1]octano-2-carboxilato de sódio
AR089631A1 (es) FORMA CRISTALINA d DE LA SAL DE ARGININA DE PERINDOPRILO, SU PROCEDIMIENTO DE PREPARACION, Y LAS COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN
WO2015062937A3 (en) Disperse dyes, their preparation and their use
ES2489467T3 (es) Polimorfo novedoso del clorhidrato del éster (6-dimetilaminometil-2-naftalenílico) del ácido (4-hidroxicarbamoilfenil)-carbámico
WO2015107542A3 (en) Tazarotene with low dimer impurity for treating acne or psoriasis
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents
WO2014054914A3 (ko) 안트라센 유도체 및 이를 포함하는 유기 발광소자
JO3276B1 (ar) طريقة لتخليق 3، 4-داي ميثوكسي باي سيكلو [4. 2. 0] أوكتا-5،3،1-تراي إين-7-كربونيتريل واستخدامها لتخليق ايفابرادين والأملاح المضافة منه مع حمض مقبول صيدلانيا.
IL237733B (en) A new crystalline phase of (&#39;4–4(3s,3s disulfanediylbis(3-aminobutane-1-sulfonic acid)) with l-lysine
RU2012128422A (ru) Способ получения 1-алкиниладамантанов
TH132008S (th) โคมไฟถนน
TH137622S (th) รางรับหลอดฟลูออเรสเซ็นต์
TH149057A (th) กระบวนการใหม่สำหรับการสังเคราะห์ของไอวาบราดีน (ivabradine) และ เกลือของมันจากการเติมด้วยกรดที่เป็นที่ยอมรับในทางเภสัชกรรม
TH148556A (th) กระบวนการใหม่สำหรับการสังเคราะห์ของไอวาบราดีน (ivabradine) และ เกลือของมันจากการเติมด้วยกรดที่เป็นที่ยอมรับในทางเภสัชกรรม
TH105339B (th) โคมไฟถนน
TH105341B (th) โคมไฟถนน
AU332087S (en) Clamping bar
TH117963A (th) คอมเพล็กซ์และวิธีผลิตนั้น ตลอดจนสารเม็ดและยาเม็ด
TH131922S (th) เสาไฟ